Another study demonstrated that NKG2D/NPs coated with mouse and human fragment crystallizable (Fc)-fusion NKG2D (Fc-NKG2D) could, through dose-dependent magnetic cell sorting, target a variety of NKG2D-ligand-positive tumor types in vitro. This evidence concerns the gene KLRK1 and neoplasm.